Microvast Holdings announces departure of chief financial officer
LEXINGTON, Mass. - Rapid Micro Biosystems , Inc. (NASDAQ:RPID) saw its shares plummet 17.8% after reporting fourth-quarter earnings that missed analyst expectations and provided disappointing guidance for the year ahead.
The life sciences technology company posted a loss of $0.22 per share for Q4, $0.01 worse than the analyst estimate of -$0.21. Revenue came in at $8.2 million, beating the consensus estimate of $7.8 million and representing a 30% increase YoY.
For the full year 2025, Rapid Micro Biosystems expects total revenue of at least $32 million, falling short of the $32.9 million analysts were anticipating. The company projects between 21 and 25 system placements for the year.
Despite the market’s negative reaction, CEO Robert Spignesi highlighted the company’s progress, stating, "We are pleased to have closed out 2024 with record fourth quarter sales and gross margin performance, demonstrating the momentum in our business."
Q4 gross margin improved to 12%, up 15 percentage points from -3% in the same quarter last year. The company placed six Growth Direct systems and completed validation of four customer systems during the quarter.
Rapid Micro Biosystems also announced a global Distribution and Collaboration Agreement with MilliporeSigma, granting the latter co-exclusive rights to sell Growth Direct systems and related consumables globally.
As of December 31, 2024, the company had $50.7 million in cash, cash equivalents, and investments, with no outstanding debt.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.